Patents by Inventor Rui Kano

Rui Kano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12121512
    Abstract: An object of the present invention is to provide an antifungal agent which is effective against cryptococcosis. The present invention provides an antifungal agent comprising ravuconazole as an active ingredient, wherein the agent is administered to an animal suffering from cryptococcosis. Further, the present invention provides an antifungal agent comprising ravuconazole as an active ingredient, wherein the agent is administered to an animal suffering from cryptococcus that is resistant to triazole-based antifungal agents selected from the group consisting of fluconazole, itraconazole and voriconazole.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: October 22, 2024
    Assignees: SEREN PHARMACEUTICALS INC., NIHON UNIVERSITY
    Inventors: Rui Kano, Osamu Ogawa
  • Publication number: 20220378752
    Abstract: The present invention has an object of providing a composition that is effective for the treatment of a prototheca disease. According to the present invention, a composition containing ravuconazole as an active ingredient, which is administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii, is provided.
    Type: Application
    Filed: July 9, 2020
    Publication date: December 1, 2022
    Applicants: SEREN PHARMACEUTICALS INC., NIHON UNIVERSITY
    Inventors: Rui KANO, Osamu OGAWA
  • Publication number: 20220142987
    Abstract: An object of the present invention is to provide an antifungal agent which is effective against cryptococcosis. The present invention provides an antifungal agent comprising ravuconazole as an active ingredient, wherein the agent is administered to an animal suffering from cryptococcosis. Further, the present invention provides an antifungal agent comprising ravuconazole as an active ingredient, wherein the agent is administered to an animal suffering from cryptococcus that is resistant to triazole-based antifungal agents selected from the group consisting of fluconazole, itraconazole and voriconazole.
    Type: Application
    Filed: April 6, 2020
    Publication date: May 12, 2022
    Applicants: SEREN PHARMACEUTICALS INC., NIHON UNIVERSITY
    Inventors: Rui Kano, Osamu Ogawa
  • Publication number: 20100136558
    Abstract: It is intended to clarify the CD20 amino acid sequence and its gene sequence which are essentially required in constructing an anti-CD20 antibody useful in treating animal malignant lymphoma. It is also intended to provide a method of diagnosing canine malignant lymphoma by using the CD20 gene sequence. Using monocytes in canine blood as a sample, mRNA is obtained and the full base sequence of canine CD20 gene (SEQ ID NO:2) is determined. Based on this sequence, its amino acid sequence (SEQ ID NO:1) is determined. Comparing the homologies with human and mouse CD20 genes and amino acid sequences, it is identified as canine CD20 gene. Moreover, a primer specific to the canine CD20 gene is constructed and the expression of the CD20 gene in a sample is examined, thereby giving a method of diagnosing canine B lymphocyte-origin malignant lymphoma.
    Type: Application
    Filed: November 12, 2009
    Publication date: June 3, 2010
    Applicant: NIHON UNIVERSITY
    Inventors: Rui KANO, Atsuhiko HASEGAWA, Chika INOUE
  • Publication number: 20080299546
    Abstract: It is intended to clarify the CD20 amino acid sequence and its gene sequence which are essentially required in constructing an anti-CD20 antibody useful in treating animal malignant lymphoma. It is also intended to provide a method of diagnosing canine malignant lymphoma by using the gene sequence. Using monocytes in canine blood as a sample, mRNA is obtained and the full base sequence of canine CD20 gene (SEQ ID NO:2) is determined. Based on this sequence, its amino acid sequence (SEQ ID NO:1) is determined. Comparing the homologies with human and mouse CD20 genes and amino acid sequences, it is identified as canine CD20 gene. Moreover, a primer specific to the canine gene is constructed and the expression of the CD20 gene in a sample is examined, thereby giving a method of diagnosing canine B lymphocyte-origin malignant lymphoma.
    Type: Application
    Filed: February 9, 2005
    Publication date: December 4, 2008
    Applicant: NIHON UNIVERSITY
    Inventors: Rui Kano, Atsuhiko Hasegawa, Chika Inoue